SCHEMBL5577853

SCHEMBL5577853

CCOC(=O)Nc1nc2[nH]nc(N)c2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.50
RAB9A P51151 4/20 0.50
NPC1 O15118 2/20 0.50
ALDH1A1 P00352 7/20 0.48
HSD17B10 Q99714 5/20 0.48
CYP1A2 P05177 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP2C9 P11712 2/20 0.48
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
ADORA3 P0DMS8 4/20 0.44
NPSR1 Q6W5P4 3/20 0.44
LMNA P02545 2/20 0.44
ADORA2B P29275 1/20 0.44
KDM4E B2RXH2 4/20 0.41
HPGD P15428 3/20 0.41
NFKB1 P19838 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755612 0.78 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL18548422 0.75 LCK (0.45) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14454808 0.73 AHR (0.52) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL10992511 0.69 RECQL (0.63) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL2313516 0.68 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL544015 0.68 ALDH1A1 (0.77) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL31167878 0.68 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL13401214 0.68 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL2666939 0.67 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL8689148 0.67 NPC1 (1.00) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
WO-2007059341-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators MAP4K2, MAP4K5, MAP4K3 SMN1; SMN2 3826/4885RAB9A 1840/4885NPC1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.